arrow
S

Sarah Buckley

sobi inc
H指数:36
被引数:7,210

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

PAXIS:一项随机、双盲、安慰剂对照、剂量探索的II期研究(第一部分),随后进行开放标签期(第二部分),以评估Pacritinib在VEXAS综合征患者中的有效性和安全性

2026-02-270
OAAI
Establishing a consensus definition of VEXAS flare for clinical research

建立VEXAS flare的临床研究共识定义

2025-12-010
PRE
Acceptability of acceptance and commitment therapy for medication-decision-making and quality of life in women with breast cancer: A qualitative process evaluation

接受与承诺疗法对乳腺癌女性在用药决策和生活质量方面的可接受性:一项定性过程评估

2025-05-130
OA
Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

血清白蛋白改善作为Pacritinib治疗患者代谢状况改善的指标:一项回顾性分析,研究对象为接受三项临床试验治疗的患者的数据。

BLOOD
IF23.1
2024-11-050
PRE
A pilot randomised controlled trial of acceptance and commitment therapy for medication decision-making and quality of life in women with breast cancer: The ACTION trial
2024-05-161
OA
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
2020-11-2465
OAAI
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
LEUKEMIA
IF13.4
2019-10-0412
PREAI
The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial
LANCET
IF88.5
2019-08-01187
OAAI
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
2018-11-0823
OAAI